S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

ZVRA Zevra Therapeutics Inc

7.65

0.00 (0.00%)

Pre Market

Last Updated: 20:00:00

Delayed by 15 minutes

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Zevra Therapeutics (NASDAQ:ZVRA)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Zevra Therapeutics Charts.

Zevra Therapeutics (NASDAQ:ZVRA)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Zevra Therapeutics Charts.

Zevra Therapeutics Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 4 February 2025 (13 hours ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 4 February 2025 (13 hours ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 4 February 2025 (13 hours ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 4 February 2025 (13 hours ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 4 February 2025 (13 hours ago) • Edgar (US Regulatory)

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™
Thursday 30 January 2025 (5 days ago) • GlobeNewswire Inc.

Zevra Therapeutics to Participate at Upcoming Investor Conferences
Thursday 30 January 2025 (6 days ago) • GlobeNewswire Inc.

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024
Tuesday 17 December 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Saturday 7 December 2024 (2 months ago) • Edgar (US Regulatory)

Zevra Therapeutics Announces Organizational Changes
Saturday 7 December 2024 (2 months ago) • GlobeNewswire Inc.

Zevra Therapeutics to Participate at Upcoming Investor Conferences
Tuesday 26 November 2024 (2 months ago) • GlobeNewswire Inc.

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C
Friday 22 November 2024 (2 months ago) • GlobeNewswire Inc.

More Zevra Therapeutics Inc News Articles

Sterling vs AUD

Westpac Banking

Newcrest Mining

Commonwealth Bank Of Aus...

Australian SE All Ordina...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions